The translational gap for gene therapies in low- and middle-income countries
Science Translational Medicine · 08.05.2024 · 16 (746)
DOI: 10.1126/scitranslmed.adn1902 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Translational Medicine, erschienen am 08.05.2024. Verfasst von Kevin W Doxzen und 18 weiteren Autor:innen. Beteiligte Einrichtung: Strategic Analysis Inc., Arlington, VA, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Developing Countries, Translational Research, Biomedical. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective treatment options for a wide range of genetic and nongenetic diseases. However, as the medical scope of gene therapies expands, consideration must be given to those who will benefit and what proactive steps must be taken to widen development and access potential, particularly in regions carrying a high disease burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Strategic Analysis Inc., Arlington, VA, USA.
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Departments of Medical Oncology and Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
- Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Brasília, Brasília, DF, Brazil.
- Sickle Cell Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health & Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.
- SickleInAfrica Clinical Coordinating Center, Muhimbili University of Health & Allied Sciences (MUHAS), Dar-es-Salaam, Tanzania.
ORCID-Profile: Kevin W Doxzen, Jennifer E Adair, Yris Maria Fonseca Bazzo, Kenneth Cornetta, Varsha Dalal, Renato Luiz Guerino-Cunha, Johnny Mahlangu, Julie Makani, Vikram Mathews, Margareth C Ozelo, Savita Rangarajan, João Batista Silva Júnior
Zitieren
APA
Doxzen, K. W., Adair, J. E., Fonseca Bazzo, Y. M., Bukini, D., Cornetta, K., Dalal, V., Guerino-Cunha, R. L., Hongeng, S., Jotwani, G., Kityo-Mutuluuza, C., Lakshmanan, K., Mahlangu, J., Makani, J., Mathews, V., Ozelo, M. C., Rangarajan, S., Scholefield, J., Batista Silva Júnior, J., & McCune, J. M. (2024). The translational gap for gene therapies in low- and middle-income countries. Science Translational Medicine, 16(746). https://doi.org/10.1126/scitranslmed.adn1902
Vancouver
Doxzen KW, Adair JE, Fonseca Bazzo YM, Bukini D, Cornetta K, Dalal V, et al. The translational gap for gene therapies in low- and middle-income countries. Science Translational Medicine. 2024;16(746). doi:10.1126/scitranslmed.adn1902
BibTeX
@article{Doxzen2024,
author = {Doxzen, Kevin W and Adair, Jennifer E and Fonseca Bazzo, Yris Maria and Bukini, Daima and Cornetta, Kenneth and Dalal, Varsha and Guerino-Cunha, Renato Luiz and Hongeng, Suradej and Jotwani, Geeta and Kityo-Mutuluuza, Cissy and Lakshmanan, Krishnamurti and Mahlangu, Johnny and Makani, Julie and Mathews, Vikram and Ozelo, Margareth C and Rangarajan, Savita and Scholefield, Janine and Batista Silva Júnior, João and McCune, Joseph M},
title = {The translational gap for gene therapies in low- and middle-income countries},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {746},
doi = {10.1126/scitranslmed.adn1902}
}
EUVIMED